Hak-Kim Chan

Professor Hak-Kim Chan of the Sydney Pharmacy School at the University of Sydney is a world-renowned expert in respiratory drug delivery, particularly pulmonary aerosols and inhalation therapies. With over 480 publications and 17,580+ Google Scholar citations, he has pioneered advancements in powder formulation, in silico modeling, and clinical applications of inhalation technologies. His work includes the development of FDA-approved diagnostics like Aridol™ (inhaled mannitol for asthma) and Bronchitol™ (for cystic fibrosis), and groundbreaking research on inhaled bacteriophage therapy to combat antibiotic-resistant respiratory infections.

• Education: BPharm (University Medal, 1983), PhD (1988), DSc (2009) from University of Sydney
• Professional Experience: Postdoc at University of Minnesota (1988–89), Scientist at Genentech Inc. (1992–95)
• Leadership: Executive Editor of Advanced Drug Delivery Reviews, Fellow of AAPS and RACI

His research spans in vitro production methods, computational modeling of inhaler design, and in vivo imaging of aerosol deposition. Current projects focus on nanomedicine, phage therapy, and combating superbugs via inhalation routes. He has secured significant recognition for his work, including NHMRC case studies highlighting public health impacts.

Professor Chan has supervised numerous researchers, including PhD student Grace YAU studying pulmonary probiotic delivery. His team's 10 patents (7 as first inventor) reflect practical innovations in dry powder inhalers, antimicrobial formulations, and drug stabilization technologies.